查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715655

肝病诊断市场（按产品、疾病类型和最终用户划分）—2025-2030 年全球预测

Liver Disease Diagnostics Market by Offering, Disease Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2024 年肝病诊断市场规模将达到 110.9 亿美元，到 2025 年将达到 125.7 亿美元，到 2030 年将达到 230.8 亿美元，复合年增长率为 12.99%。

主要市场统计数据
基准年2024年 110.9亿美元
预计2025年 125.7亿美元
预测年份 2030 230.8亿美元
复合年增长率（%） 12.99%

在快速发展的肝病诊断领域，创新和精确比以往任何时候都更重要。本报告深入探讨了改变肝病诊断和治疗方法的变化。报告首先清楚地阐述了推动产业向更准确、更可靠、更少侵入性的诊断方法发展的市场动态。关键驱动因素包括技术进步、临床方法的不断改进以及对早期检测和个人化治疗计划的需求不断增加。

本分析采用整体视角，有系统地探讨影响市场动态的最新趋势、新兴挑战和突破性发展。肝病是全球面临的重大健康挑战，加强诊断通讯协定对于减少严重后果和优化患者照护至关重要。这项全面的介绍为后续章节奠定了基础，包括各种细分考虑、区域分析、竞争格局和可行的建议，旨在为决策者和行业专家提供新兴的商业机会和策略必要事项。

肝病诊断市场的转型

近年来，由于技术的快速进步和临床方法的不断发展，肝病诊断领域发生了显着变化。诊断影像和微创手术的重大创新彻底改变了肝病的检测方式。人们越来越重视生物标记的开发以及人工智慧和诊断成像的整合，这对于提高诊断的准确性和速度至关重要。曾经严重依赖传统影像的调查方法现在得到了尖端血液测试和先进内视镜手术的补充。

随着临床实践的发展，新切片检查技术的采用正在提高患者的安全性和诊断的可靠性。这种演变也回应了日益增长的早期检测需求，其中简化的流程和更短的手术时间受到高度重视。数位健康解决方案与传统诊断方法之间的协同效应将实现无缝的患者体验，使医疗保健提供者更容易监测后续观察和病情进展。

这些变革趋势不仅重塑了临床工作流程，而且还影响了医疗保健相关人员的更广泛策略。透过适应这种不断变化的形势，行业相关人员可以提供可自订的综合诊断解决方案，满足患者的特定需求，最终改善临床结果。

肝病诊断的关键细分洞察

在了解肝病诊断市场时，关键的细分洞察是支柱。第一次细分是透过各种诊断方法来细分市场。在切片检查技术领域，已经探索了腹腔镜、经皮和经静脉方法，每种方法都旨在平衡侵入性和诊断准确性。同样，血液检查侧重于各种酶的评估，例如丙氨酸转氨酶、天冬氨酸转氨酶和γ-谷氨酰转肽酶测试，以提供对肝功能和肝损伤的细緻了解。同时，在影像诊断方面，我们将深入研究不同精确度的检查方式，包括电脑断层扫描、MRI 和超音波。

第二个细分捕捉疾病的类型，从急性肝炎和酒精性肝病到慢性肝炎、肝硬化、肝细胞癌和非酒精性脂肪肝病。透过这种维度分析，我们可以深入了解每种肝病的诊断挑战和资源需求。最后，基于最终用户的细分检验了诊断实验室、医院和研究机构中诊断技术的多样化部署。每个细分不仅揭示了临床和业务动态，还揭示了不同垂直市场中的技术部署和业务成长机会。

这些市场区隔洞察可以为相关人员提供清晰的思路，使他们能够瞄准市场中的特定领域，完善产品系列，并调整策略倡议，以应对频谱肝臟相关疾病中独特的诊断挑战。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 认识到肝臟诊断的需求日益增长以及早期诊断的努力
      • 医疗成本的上涨促使对肝病诊断服务的投资增加
      • 全球性肝病的发生率不断上升，对诊断的需求也随之增加。
    • 限制因素
      • 先进诊断程序高成本
    • 机会
      • 技术进步促进了更准确、侵入性更小的诊断方法的发展
      • 人们对远距肝病监测和诊断的远端医疗解决方案的兴趣日益浓厚
    • 任务
      • 新诊断工具的监管更加严格，核准流程也更加冗长
  • 市场区隔分析
    • 图片来源：内视镜检查在食道静脉曲张的检测和治疗中的重要性日益增加
    • 最终用户：医院越来越多地采用肝病诊断来提供即时检测和干预策略
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章肝病诊断市场（按类型）

  • 切片检查技术
    • 腹腔镜切片检查
    • 经皮肝切片检查
    • 静脉肝切片检查
  • 血液检查
    • 丙氨酸转氨酶检测
    • 天门冬胺酸转氨酶检测
    • γ-谷氨酰转肽酶检测
  • 内视镜检查
  • 影像学诊断
    • 电脑断层扫描
    • MRI
    • 超音波

第七章肝病诊断市场（依疾病类型）

  • 急性肝炎
  • 酒精性肝臟疾病
  • 慢性肝炎
  • 肝硬化
  • 肝细胞癌
  • 非酒精性脂肪肝

第八章肝病诊断市场（按最终用户）

  • 诊断实验室
  • 医院
  • 研究组织

9.美洲肝病诊断市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

10.亚太地区肝病诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第 11 章欧洲、中东和非洲肝病诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • Amgen Inc.
  • Argon Medical Devices, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Boston Scientific Corporation
  • Cook Medical Incorporated
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • Hepatiq, Inc.
  • Hologic, Inc.
  • Horiba, Ltd.
  • Koninklijke Philips NV
  • Laboratory Corporation of America Holdings
  • Medtronic PLC
  • Merck & Co., Inc.
  • Perspectum Ltd.
  • Quest Diagnostics Incorporated
  • Randox Laboratories Ltd.
  • Ri.Mos. Srl
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-B9334AD6C587

The Liver Disease Diagnostics Market was valued at USD 11.09 billion in 2024 and is projected to grow to USD 12.57 billion in 2025, with a CAGR of 12.99%, reaching USD 23.08 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 11.09 billion
Estimated Year [2025] USD 12.57 billion
Forecast Year [2030] USD 23.08 billion
CAGR (%) 12.99%

In the rapidly evolving realm of liver disease diagnostics, innovation and precision are more critical than ever. This report offers a deep dive into the transformative shifts reshaping how liver disorders are diagnosed and managed. The discussion begins with a clear articulation of prevailing market dynamics that are steering industry evolution towards more accurate, reliable, and less invasive diagnostic procedures. Key drivers include advances in technology, a continuous refinement in clinical practices, and the growing demand for early-stage detection coupled with personalized treatment plans.

The analysis takes a holistic view, systematically exploring the latest trends, emerging challenges, and breakthrough developments influencing market behavior. With liver disease presenting a significant health challenge globally, enhanced diagnostic protocols are critical in mitigating severe outcomes and optimizing patient care. This comprehensive introduction sets the stage for the subsequent sections that navigate through various segmentation insights, regional analyses, the competitive landscape, and actionable recommendations, all crafted to inform decision-makers and industry experts on emerging opportunities and strategic imperatives.

Transformative Shifts in the Liver Disease Diagnostics Landscape

Recent years have witnessed transformative shifts across the liver disease diagnostics landscape, driven by rapid technological advancements and evolving clinical approaches. Significant innovations in imaging modalities and minimally invasive procedures have revolutionized detection methods. There is an increasing emphasis on developing biomarkers and integrating artificial intelligence with diagnostic imaging, which has been critical in enhancing the accuracy and speed of diagnoses. Methodologies that once relied heavily on traditional imaging are now being complemented by state-of-the-art blood-based tests and sophisticated endoscopic procedures.

As clinical practices evolve, the adoption of novel biopsy techniques has improved both patient safety and diagnostic reliability. This evolution is also a response to the escalating demand for early detection, where streamlined processes and reduced procedure times are highly valued. The synergy between digital health solutions and traditional diagnostic methods enables a seamless patient experience, making it easier for health care providers to conduct follow-ups and monitor disease progression.

These transformative trends are not only reshaping clinical workflows but also influencing the broader strategies of healthcare stakeholders. By embracing this landscape of change, industry participants are better positioned to deliver integrated diagnostic solutions that are customizable and responsive to patient-specific needs, ultimately driving enhanced clinical outcomes.

Key Segmentation Insights in Liver Disease Diagnostics

Critical segmentation insights form the backbone of understanding the liver disease diagnostics market. The first segmentation focuses on offerings, segmenting the market through diverse diagnostic methods. In the realm of biopsy techniques, the investigation spans laparoscopic, percutaneous, and transvenous approaches, each crafted to balance invasiveness with diagnostic accuracy. Similarly, blood-based tests are dissected by focusing on different enzyme assessments that include alanine transaminase, aspartate transaminase, and gamma-glutamyl transpeptidase tests, providing nuanced insights into liver function and damage. Meanwhile, imaging diagnostics are evaluated by delving into modalities such as CT scans, MRI, and ultrasound, which offer varying levels of precision and are integral in both acute and chronic assessments.

The second segmentation captures disease types, ranging from acute hepatitis and alcoholic liver disease to chronic hepatitis, cirrhosis, hepatocellular carcinoma, and non-alcoholic fatty liver disease. This dimensional analysis ensures that each liver condition is explored in terms of its unique diagnostic challenges and resource requirements. Lastly, segmentation based on end-users provides an examination of the varied deployment of diagnostic technologies across diagnostic laboratories, hospitals, and research institutes. Each segment not only highlights distinct clinical and operational dynamics but also reveals tailored opportunities for technology deployment and business growth in different market verticals.

These segmentation insights collectively empower stakeholders with the clarity needed to target specific niches within the market, refine product portfolios, and align strategic initiatives to address unique diagnostic challenges across the spectrum of liver-related diseases.

Based on Offering, market is studied across Biopsy Techniques, Blood-Based Tests, Endoscopy, and Imaging Diagnostics. The Biopsy Techniques is further studied across Laparoscopic Liver Biopsy, Percutaneous Liver Biopsy, and Transvenous Liver Biopsy. The Blood-Based Tests is further studied across Alanine Transaminase Test, Aspartate Transaminase Test, and Gamma-Glutamyl Transpeptidase Test. The Imaging Diagnostics is further studied across CT Scan, MRI, and Ultrasound.

Based on Disease Type, market is studied across Acute Hepatitis, Alcoholic Liver Disease, Chronic Hepatitis, Cirrhosis, Hepatocellular Carcinoma, and Non-Alcoholic Fatty Liver Disease.

Based on End-User, market is studied across Diagnostic Laboratories, Hospitals, and Research Institutes.

Assessing Regional Variations in Liver Disease Diagnostics

A regional assessment of the liver disease diagnostics market reveals significant geographic variations that influence market dynamics and growth trajectories. In the Americas, robust healthcare infrastructures and a pronounced focus on early disease detection have paved the way for the adoption of advanced diagnostic modalities. The region also benefits from extensive research and development investments, driving innovations that are rapidly integrated into clinical practices.

Across Europe, the Middle East, and Africa, diverse healthcare systems and regulatory frameworks have resulted in a dynamic, albeit fragmented, market landscape. Here, the interplay of governmental policies, reimbursement strategies, and regional disease prevalence creates both challenges and opportunities for diagnostic technology manufacturers. In these regions, collaborations between public and private healthcare providers are instrumental in facilitating the diffusion of diagnostic innovations.

The Asia-Pacific region presents a contrast, characterized by burgeoning healthcare markets, a large patient pool, and an increasing prevalence of lifestyle-related liver conditions. The region's rapid economic development and shifting disease patterns are compelling market players to adapt their strategies to meet the rising demand for cutting-edge diagnostic services. An increased focus on healthcare accessibility, combined with ongoing investments in medical technology facilities, is gradually transforming the diagnostic landscape in Asia-Pacific into one of the most vibrant and competitive globally.

These regional insights underscore the importance of tailored marketing strategies and localized product development to effectively respond to unique regional dynamics and optimize market penetration.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape and Leading Companies in Liver Disease Diagnostics

The competitive landscape in liver disease diagnostics is marked by robust innovation and strategic maneuvering by key market players. Leading companies have distinguishably played catalytic roles in shaping this market by deploying state-of-the-art diagnostic solutions and continuously refining their product portfolios. Prominent industry players such as Abbott Laboratories, Amgen Inc., and Argon Medical Devices, Inc. are at the forefront, leveraging expansive research networks and advanced technologies to secure competitive advantages.

Other influential companies include Bayer AG, Becton, Dickinson and Company, and Bio-Rad Laboratories, Inc. Their strategic focus on integrating diagnostic tests with streamlined clinical procedures has significantly reduced the turnaround time in diagnosing liver conditions. BioMerieux SA, Boston Scientific Corporation, and Cook Medical Incorporated have also cemented their positions through continuous innovation, backed by extensive clinical validation studies and rigorous R&D initiatives.

The market has further been invigorated by the contributions of Epigenomics AG and F. Hoffmann-La Roche Ltd., whose efforts in precision diagnostics are well recognized. Companies such as Fujifilm Holdings Corporation, Hepatiq, Inc., and Hologic, Inc. continue to expand their technological capabilities by forging strategic partnerships and investing in next-generation diagnostic platforms. Horiba, Ltd., Koninklijke Philips N.V., and Laboratory Corporation of America Holdings have demonstrated a consistent trajectory of growth by focusing on market-specific demands that encompass both chronic and acute liver disease diagnostics.

Recognized leaders in the field such as Medtronic PLC, Merck & Co., Inc., Perspectum Ltd., Quest Diagnostics Incorporated, and Randox Laboratories Ltd. further underscore the market's competitive intensity. Companies including Ri.Mos. Srl, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc. finalize this comprehensive roster of industry trailblazers, each contributing significantly to the evolution of diagnostic procedures with their dynamic range of product offerings and pioneering solutions in the liver disease diagnostics arena.

The report delves into recent significant developments in the Liver Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., Argon Medical Devices, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMerieux SA, Boston Scientific Corporation, Cook Medical Incorporated, Epigenomics AG, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, Hepatiq, Inc., Hologic, Inc., Horiba, Ltd., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Medtronic PLC, Merck & Co., Inc., Perspectum Ltd., Quest Diagnostics Incorporated, Randox Laboratories Ltd., Ri.Mos. Srl, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc.. Strategic Recommendations for Industry Leaders

For industry leaders looking to navigate the dynamic and competitive landscape of liver disease diagnostics, several strategic recommendations can be drawn from emerging trends and market insights. Leaders are encouraged to focus on research and development initiatives that prioritize precision and minimally invasive diagnostic techniques. Investing in technologies that synergistically combine imaging modalities, blood-based tests, and biopsy techniques can significantly enhance diagnostic accuracy and improve patient outcomes.

Another key recommendation is to cultivate robust partnerships with research institutes and hospitals. This collaborative approach not only broadens the scope of clinical trials but also accelerates the adoption of new diagnostic methods. Aligning product innovation with regional market needs, particularly in rapidly growing areas like Asia-Pacific, ensures that solutions are both relevant and timely.

Industry players should also consider diversifying their product offerings to address the multifaceted nature of liver diseases. The market calls for an integrated approach that spans from acute to chronic conditions, and offering segmented solutions for different disease types is imperative. Furthermore, maintaining transparency around clinical efficacy and regulatory compliance will strengthen stakeholder trust and drive market acceptance.

Finally, leveraging digital health platforms to streamline patient data and integrate real-time analytics will empower stakeholders with actionable insights, thereby fostering a proactive rather than reactive approach in disease management. These recommendations collectively form a blueprint aimed at sustaining competitive advantage and fostering long-term growth in the liver disease diagnostics market.

Conclusion: Shaping the Future of Liver Disease Diagnostics

In conclusion, the liver disease diagnostics market stands at a pivotal juncture, characterized by significant technological advancements, evolving segmentation insights, and diverse regional dynamics. The comprehensive examination of offering-based segmentation, disease-specific demands, and end-user needs reveals a market that is both complex and ripe with opportunity. Embracing transformative shifts, such as the integration of digital health tools and the adoption of advanced diagnostic techniques, has set the foundation for enhanced clinical outcomes.

The competitive landscape, driven by innovation from top companies, underscores the importance of continuous improvement and strategic agility. By aligning product development with evolving patient needs and regulatory environments, industry leaders can effectively address the challenges inherent in diagnosing liver diseases and drive superior value for healthcare providers and patients alike.

Taken together, the insights and data presented in this report provide a nuanced understanding of the current and future trends in liver disease diagnostics. The path ahead is filled with both challenges and opportunities that, when navigated effectively, can lead to groundbreaking advancements and improved healthcare outcomes across the globe.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness and early diagnosis initiatives expanding the need for liver diagnostics
      • 5.1.1.2. Rising healthcare expenditure contributing to improved investment in liver disease diagnostic services
      • 5.1.1.3. Rising prevalence of liver diseases globally which is increasing the demand for diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of advanced diagnostic procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements contributing to the development of more precise and less invasive diagnostic methods
      • 5.1.3.2. Growing interest in telehealth solutions for remote liver disease monitoring and diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Stricter regulations and lengthy approval process for new diagnostic tools
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Rising significance of endoscopy for detecting and managing esophageal varices
    • 5.2.2. End-User: Growing adoption of liver disease diagnostics in hospitals to offer immediate testing and intervention strategies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Liver Disease Diagnostics Market, by Offering

  • 6.1. Introduction
  • 6.2. Biopsy Techniques
    • 6.2.1. Laparoscopic Liver Biopsy
    • 6.2.2. Percutaneous Liver Biopsy
    • 6.2.3. Transvenous Liver Biopsy
  • 6.3. Blood-Based Tests
    • 6.3.1. Alanine Transaminase Test
    • 6.3.2. Aspartate Transaminase Test
    • 6.3.3. Gamma-Glutamyl Transpeptidase Test
  • 6.4. Endoscopy
  • 6.5. Imaging Diagnostics
    • 6.5.1. CT Scan
    • 6.5.2. MRI
    • 6.5.3. Ultrasound

7. Liver Disease Diagnostics Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Acute Hepatitis
  • 7.3. Alcoholic Liver Disease
  • 7.4. Chronic Hepatitis
  • 7.5. Cirrhosis
  • 7.6. Hepatocellular Carcinoma
  • 7.7. Non-Alcoholic Fatty Liver Disease

8. Liver Disease Diagnostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals
  • 8.4. Research Institutes

9. Americas Liver Disease Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Liver Disease Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Liver Disease Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. FPNV Positioning Matrix, 2024
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Argon Medical expands liver diagnostics portfolio with innovative device launches
    • 12.3.2. Apollo hospitals unveils advanced fatty liver clinic with innovative diagnostic and treatment solutions
    • 12.3.3. Quibim unveils QP-liver for enhanced AI-driven diagnosis of diffuse liver diseases
    • 12.3.4. E-Scopics Announces Commercial Launch Of Hepatoscope in the Us And Opens its Subsidiary in the US
    • 12.3.5. Stone Diagnostics to Provide Fibronostics Liver Disease Test
    • 12.3.6. Predictive Health Intelligence Launches Tool For Undiagnosed Liver Disease
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Amgen Inc.
  • 3. Argon Medical Devices, Inc.
  • 4. Bayer AG
  • 5. Becton, Dickinson and Company
  • 6. Bio-Rad Laboratories, Inc.
  • 7. BioMerieux SA
  • 8. Boston Scientific Corporation
  • 9. Cook Medical Incorporated
  • 10. Epigenomics AG
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Fujifilm Holdings Corporation
  • 13. Hepatiq, Inc.
  • 14. Hologic, Inc.
  • 15. Horiba, Ltd.
  • 16. Koninklijke Philips N.V.
  • 17. Laboratory Corporation of America Holdings
  • 18. Medtronic PLC
  • 19. Merck & Co., Inc.
  • 20. Perspectum Ltd.
  • 21. Quest Diagnostics Incorporated
  • 22. Randox Laboratories Ltd.
  • 23. Ri.Mos. Srl
  • 24. Siemens Healthineers AG
  • 25. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. LIVER DISEASE DIAGNOSTICS MARKET MULTI-CURRENCY
  • FIGURE 2. LIVER DISEASE DIAGNOSTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. LIVER DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 4. LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 15. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 17. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. LIVER DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 23. LIVER DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LIVER DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LIVER DISEASE DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. LIVER DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 286. LIVER DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024